What are the challenges in treating MDR-TB?

Question

Hello doctor,

My cousin was recently diagnosed with meningitis, and tests revealed it is caused by multidrug-resistant tuberculosis (MDR-TB). This combination seems particularly alarming. What are the unique challenges in treating meningitis caused by MDR-TB? How does this affect the prognosis compared to regular meningitis or TB? What treatment options are available, given the drug resistance? Are there any new or experimental treatments we should consider? What are the risks of transmission to family members? How long is the expected treatment duration? What long-term effects might my cousin face? Are there specialized care facilities for such complex cases? Kindly help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

Meningitis(inflammation of the tissues surrounding the brain and spinal cord) is caused by multidrug-resistant tuberculosis (MDR-TB) (Tuberculosis is caused by bacterial resistance to first-line anti-tuberculosis drugs, like Isoniazid and Rifampicin.). MDR-TB is resistant to at least two of the first-line anti-TB drugs, Isoniazid and Rifampicin.

Meningitis complicates this further because many tuberculosis drugs struggle to cross the blood-brain barrier, making it harder to deliver effective concentrations of the drug to the site of infection in the brain.

Meningitis is an inflammation of the protective membranes covering the brain and spinal cord, which can lead to severe complications such as brain damage, hearing loss, and neurological deficits.

The combination of drug-resistant tuberculosis and meningitis makes the illness more difficult to treat and increases the risk of consequences. The medications available for MDR-TB are less effective and slower-acting than those used for drug-sensitive tuberculosis treatment (a type of tuberculosis that can be treated with drugs), which means that the infection may take longer to respond. MDR-TB and meningitis have a poor prognosis because of their clinical features, which show high death rates and long-term neurological damage.

Treatments for MDR-TB meningitis include:

Treatment for MDR-TB meningitis typically lasts 18-24 months, unlike pulmonary MDR-TB. It is recommended to treat issues such as increased intracranial pressure and seizures (uncoordinated bodily movements).
Second-line anti-TB medications.
Injectable agents.

Newer treatments include:

Newer TB medications may be considered, but their usage is limited after a doctor's physical examination.
Participation in clinical trials may provide access to investigational medicines or drug combinations that are not generally available.
Strict infection control measures are indicated.
Wearing masks.
Good ventilation.
Isolating the patient.
Ototoxicity (a medication side effect involving damage to your inner ear.) from certain TB drugs can lead to hearing loss.

However, prolonged treatment can cause anxiety and depression. Periodic follow-up with the doctor is essential. TB normally spreads through airborne droplets released when an infected person coughs, sneezes or speaks. MDR-TB is not as contagious as ordinary TB, but it is more difficult to treat.

I hope this information will help you.

Kindly revert in case of queries.

Thank you.